Cited by 316Heart Failure Treatment and ManagementCardiovascular Function and Risk FactorsRenin-Angiotensin System Studies

Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators.

Konstam, M A, Kronenberg, M W, Rousseau, M F, Udelson, J E, Melin, J, Stewart, D, Dolan, N, Edens, T R +2 more·1993·Circulation

Abstract

BACKGROUND: Patients with heart failure and reduced left ventricular (LV) ejection fraction (EF) manifest progressive LV dilatation, which is prevented by angiotensin converting enzyme (ACE) inhibitors. In patients with asymptomatic LV systolic dysfunction, in whom there is less activation of the renin-angiotensin system, ventricular remodeling might be less rapid and the benefit of ACE inhibitors less discernible. METHODS AND RESULTS: One hundred eight patients enrolled in the Studies of Left Ventricular Dysfunction (SOLVD) Prevention Trial, with left ventricular ejection fraction < or = 0.35 but without clinical heart failure, underwent radionuclide ventriculograms, and 49 underwent left heart catheterizations. Measurements were made before and after double-blinded randomization to enalapril (2.5 to 20 mg/d) or placebo. Repeated-measures analysis of all time points showed significant differences for change in end-diastolic volume (EDV) between enalapril and placebo groups. Significant difference between the enalapril and placebo groups (P < .05) was present for change in EDV at 1 year within the catheterization study and at a mean of 25 months within the radionuclide study. Radionuclide EDV increased in placebo patients (119 +/- 28 to 124 +/- 33 mL/m2, mean +/- SD) and decreased in enalapril patients (120 +/- 25 to 113 +/- 25 mL/m2). Differences between the two groups were significantly less than previously described in patients with symptomatic heart failure (P < .02), with less increase in LV volumes in the placebo group and less decrease in volumes in the enalapril group. CONCLUSIONS: Chronic ACE inhibitor treatment slows or reverses LV dilatation in patients with asymptomatic LV systolic dysfunction. Compared with symptomatic patients, asymptomatic patients manifest a slower rate of spontaneous LV dilatation and less reduction in LV volumes by enalapril.

Integrity signals

Registry

Crossref · 10.1161/01.cir.88.5.2277

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • When modeling the response to antihypertensive therapies, the influence of angiotensin II on cardiac muscle must be taken into account to simulate decrease in blood pressure without increasing heart rate.

    “Thus, when modeling the response to antihypertensive therapies, the influence of angiotensin II on cardiac muscle must be taken into account to simulate decrease in blood pressure without increasing heart rate, which, for instance, is the standard effect of such RAAS inhibitors as aliskiren, losartan, and enalapril (Konstam et al., 1993; Kamishirado et al., 1997; González-Abraldes et al., 2001;”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Konstam, M. A., Kronenberg, M. W., Rousseau, M. F., Udelson, J. E., Melin, J., Stewart, D., Dolan, N., Edens, T. R., Ahn, S., & Kinan, D.
Affiliations
Tufts University (US)
Venue
Circulation
Published
1993-11
Volume
88
Issue
5
Pages
2277-2283
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W1981884097
Cited by
316
References
22
Citations by year
2026: 3 · 2025: 3 · 2024: 5 · 2023: 11 · 2022: 2 · 2021: 7 · 2020: 9 · 2019: 10 · 2018: 7 · 2017: 17 · 2016: 5 · 2015: 3 · 2014: 9 · 2013: 6 · 2012: 10
FWCI
7.94
Type
journal article
Language
en
Open access
closed
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (n01hc055010-009)
  • National Heart, Lung, and Blood Institute (N01-HC-55010)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Keywords
enalapril, ACE inhibitors, left ventricular dilatation, left ventricular systolic dysfunction, asymptomatic heart failure, ventricular remodeling, end-diastolic volume, left ventricular ejection fraction, renin-angiotensin system, heart failure prevention
MeSH terms
Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Blood Volume, Enalapril, Female, Cardiac Catheterization, Heart Diseases, Humans, Male, Middle Aged, Systole, Time Factors, Vasodilation, Radionuclide Ventriculography, Ventricular Function, Left

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review